07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Liver X receptor (LXR)

Cardiovascular disease INDICATION: Atherosclerosis Mouse and patient sample studies suggest promoting LXR expression with 2-hydroxypropyl-β-cyclodextrin (HPBCD) could help treat atherosclerosis. In primary mouse macrophages and carotid atherosclerotic plaque samples from patients, HPBCD increased expression of LXR target...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

ALX-101: Phase IIa started

Alexar began a double-blind, placebo-controlled, U.S. Phase IIa trial of 2 dose levels of ALX-101 topical gel in 72 patients. Alexar Therapeutics Inc., Malvern, Pa.   Product: ALX-101   Business: Dermatology   Molecular target: Liver X...
08:00 , Feb 5, 2015 |  BC Innovations  |  Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Financial News

Alexar Therapeutics completes venture financing

Alexar Therapeutics Inc., Malvern, Pa.   Business: Dermatology   Date completed: 1/2/14   Type: Venture financing   Raised: $21.5 million   Investors: New Science Ventures; Third Point; Palo Alto Investors   ...
08:00 , Jan 6, 2014 |  BioCentury  |  Finance

X marks the spot

X marks the spot Alexar Therapeutics Inc. isn't going after a novel target - LXR has been around for decades - but the newco is one of only two biotechs developing a topical agonist of the...
00:53 , Jan 3, 2014 |  BC Extra  |  Financial News

Alexar debuts with $21.5 million in series A

Alexar Therapeutics Inc. (Malvern, Pa.) debuted with $21.5 million secured in a series A round led by New Science Ventures and Third Point Ventures. Palo Alto Investors also participated. Alexar is developing liver X receptor...